Prediction of the Mechanism of Shaoyao Gancao Decoction in the Treatment of Alopecia Areata by Network Pharmacology and Its Preliminary Verification Study

April 2022 in “ Evidence-based Complementary and Alternative Medicine ”

Shuying Lv, Lei Wang, Yuhang Duan, Dan Huang, Dingquan Yang

Shaoyao Gancao decoction alopecia areata IL-6 PTGS2 TNF PI3K-Akt pathway Jak-STAT pathway quercetin PI3K AKT proteins SGD AA

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Quercetin →

Studysummary This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway. Our plain-language summary of this paper — not a Tressless recommendation.

The study investigated the mechanism of Shaoyao Gancao Decoction (SGD) in treating alopecia areata (AA) using network pharmacology and preliminary verification through animal experiments. Researchers identified 102 active ingredients in SGD and constructed a bioinformatics network to predict key targets and pathways, highlighting genes such as IL-6, PTGS2, and TNF. The study involved 30 female C57BL/6J mice, with results indicating that SGD could regulate immune responses and upregulate PI3K and AKT protein expression, supporting its potential therapeutic effects. However, the study emphasized the need for further research to confirm these findings and deepen understanding of SGD's mechanisms in AA treatment.

View this study on downloads.hindawi.com →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , September 2019 in “Journal of the European Academy of Dermatology and Venereology”

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations , September 2018 in “Journal of the American Academy of Dermatology”

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

research Alopecia Areata, Thyroiditis, and Vitiligo Vulgaris in a Japanese Patient with Smoldering Type Adult T-Cell Leukemia/Lymphoma

3 citations , September 2016 in “The Journal of Dermatology”

This letter to the editor discusses the occurrence of alopecia areata, thyroiditis, and vitiligo in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma, but it reports no new research findings.

Total Glucosides of Paeony Capsule Plus Compound Glycyrrhizin Tablets for the Treatment of Severe Alopecia Areata in Children: A Randomized Controlled Trial

research Total Glucosides of Paeony Capsule Plus Compound Glycyrrhizin Tablets for the Treatment of Severe Alopecia Areata in Children: A Randomized Controlled Trial

20 citations , January 2013 in “Evidence-based complementary and alternative medicine”

This study found that TGPC plus CGT was more effective than CGT alone in reducing alopecia areata severity in children over 12 months, with similar safety profiles.